4//SEC Filing
YOUNG WILLIAM D 4
Accession 0001209191-20-000298
CIK 0000875320other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 4:21 PM ET
Size
17.8 KB
Accession
0001209191-20-000298
Insider Transaction Report
Form 4
YOUNG WILLIAM D
Director
Transactions
- Sale
Common Stock
2019-12-30$218.93/sh−21,798$4,772,236→ 10,111 total - Sale
Common Stock
2019-12-30$220.25/sh−500$110,125→ 9,611 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-12-30−30,000→ 0 totalExercise: $65.65Exp: 2024-05-06→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2019-12-30$65.65/sh+30,000$1,969,500→ 39,311 total - Sale
Common Stock
2019-12-30$221.16/sh−300$66,348→ 9,311 total - Sale
Common Stock
2019-12-30$218.05/sh−7,402$1,614,006→ 31,909 total
Footnotes (7)
- [F1]Transaction made pursuant to Mr. Young's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $218.05 (range $217.50 to $218.49).
- [F3]Mr. Young undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $218.93 (range $218.50 to $219.47).
- [F5]Open market sales reported on this line occurred at a weighted average price of $220.25 (range $219.90 to $220.73).
- [F6]Open market sales reported on this line occurred at a weighted average price of $221.16 (range $221.09 to $221.30).
- [F7]Fully vested.
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001217420
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 4:21 PM ET
- Size
- 17.8 KB